Pieter Rutter Cullis (born 1946)

Pieter Rutter Cullis on Apr 17 2022https://www.youtube.com/watch?app=desktop&v=CwY5ZDWofJ0Source : An Interview with Prof. Peter Cullis : Lipid nanoparticle and new vaccine technologyApr 17, 2022 Channel : Prince Mahidol Award Conference2022-04-17-youtube-youtube-prince-mahidol-award-conference-pieter-cullis-interview-image-720p.jpghttps://drive.google.com/file/d/1bs0E506tUwn8J5Niq5sPJ9vzZWPyehT4/view?usp=share_link 

Wikipedia 🌐 Pieter Cullis 

Niece - https://en.wikipedia.org/wiki/Severn_Cullis-Suzuki 

Brother-in-law : https://en.wikipedia.org/wiki/David_Suzuki    (who married Tara Elizabeth Cullis ) 

ASSOCIATIONS - People

Associations - Companies

Saved Wikipedia (Sep 18, 2023) for "Pieter Cullis"

https://en.wikipedia.org/wiki/Pieter_Cullis

2023-09-18-wikipedia-org-pieter-cullis.pdf

Pieter Rutter Cullis OC OBC FRS is a Canadian physicist and biochemist known for his contributions to the field of lipid nanoparticles (LNP).[2] Lipid nanoparticles are essential to current mRNA vaccines as a delivery system. Prof. Cullis is best known for the development of ionizable cationic lipids. These lipids are able to complex with negatively charged nucleic acids at low pH (≈4.0) where they are positively charged because they have a pKa if approximately 6.4. They reduce or eliminate toxicity associated with cationic lipids at physiological pH of 7.4 because they adopt a net neutral charge. Finally, they enable endosomal escape because they again become positively charged in acidified endosomes and promote formation of non-bilayer structures by interaction with negatively charged lipids.[3] These properties are critical to the function of the mRNA vaccines and are rapidly enabling gene therapy in clinical settings.[4]

Cullis co-founded several companies to develop and commercialize LNP technology including [Acuitas Therapeutics], Integrated Nanotherapeutics and Precision NanoSystems.[5][6]

Research

Cullis received a PhD in physics from the University of British Columbia and then moved to Oxford Universityto work as a postdoctoral fellow in biochemistry working on NMR. During his time at Oxford, he started to work on lipids.[7] In the 1980s, he established his own laboratory at the University of British Columbia and started to create lipid bilayers. He subsequently founded Inex Pharmaceuticals, a company that focused research on ways to encapsulate drugs and nucleic acids within lipid particles.[7] He worked on the development of Patisiran, a drug that uses small interfering RNA delivered via lipid nanoparticles and was FDA approved in 2018. In collaboration with Toshifumi Yokota his research team is also developing LNPs for the treatment of muscular dystrophy.[8]

Awards and honours

References

2022 (Oct 25) 

2022-10-25-youtube-canada-gairdner-awards-pieter-cullis-manitoba-lecture-720p.mp4

2022-10-25-youtube-canada-gairdner-awards-pieter-cullis-manitoba-lecture-720p-hits-cover-1080p.jpg

https://www.youtube.com/watch?v=qZYa7SGz87U

2022 University of Manitoba Gairdner Lecture by Dr. Pieter Cullis

CanadaGairdnerAwards

671 views  Oct 25, 2022

Dr. Pieter Cullis, 2022 Canada Gairdner International Award winner presented at the University of Manitoba for the Annual Gairdner Lecture - Science and Serendipity: Lipid Nanoparticles that Enable COVID-19 MRNA Vaccines.